As cancer drug development progresses, it will be important to take into consideration the potential for these PI3K inhibitors to greatly diminish NK-cell recognition and cytolysis of targets; especially because NK cells are important for recognition and clearance of tumor cells [2]. The gene discussed is PIK3CD; the disease is cancer.